Open access

Epidemiology of Alzheimer’s Disease

Written By

Weili Xu, Camilla Ferrari and Hui-Xin Wang

Submitted: April 24th, 2012 Published: February 27th, 2013

DOI: 10.5772/54398

Chapter metrics overview

3,709 Chapter Downloads

View Full Metrics

1. Introduction

1.1. Global aging

The aging of populations has become a worldwide phenomenon [1]. In 1990, 26 nations had more than two million elderly citizens aged 65 years and older, and the projections indicate that an additional 34 countries will join the list by 2030. In 2000, the number of old people (65+ years) in the world was estimated to be 420 million and it was projected to be nearly one billion by 2030, with the proportion of old people increasing from 7 to 12%. The largest increase in absolute numbers of old people will occur in developing countries; it will almost triple from 249 million in 2000 to an estimated 690 million in 2030. The developing regions' sharing the worldwide aging population will increase from 59 to 71% [2]. Developed countries, which have already shown a dramatic increase in people over 65 years of age will experience a progressive aging of the elderly population. Underlying global population aging is a process known as the “demographic transition” in which mortality and then fertility decline [3]. Decreasing fertility and lengthening life expectancy have together reshaped the age structure of the population in most regions of the planet by shifting relative weight from younger to older groups.

Both developed and developing countries will face the challenge of coping with a high frequency of chronic conditions, such as dementia, which is a characteristic of aging societies. These conditions impair the ability of older persons to function optimally in the community and reduce well-being among affected individuals and their families. Further, these conditions are associated with significant health care costs that must be sustained by the society at large. Thus, the global trend in the phenomenon of population aging has a dramatic impact on public health, healthcare financing and delivery systems throughout the world [4]. Due to the aging of the population, dementia has become a major challenge to elderly care and public health.

1.2. Dementia and Alzheimer’s disease

Dementia is defined as a clinical syndrome, and characterized by the development of multiple cognitive deficits that are severe enough to interfere with daily functioning, including social and professional functioning. The cognitive deficits include memory impairment and at least one of the other cognitive domains, such as aphasia, apraxia, agnosia or disturbances in executive functioning [5, 6]. Alzheimer’s disease is the most common cause of dementia in the elderly, accounting for 60-70% of all demented cases [7]. Alzheimer’s disease is strictly a neuropathological diagnosis determined by the presence of neurofibrillary tangles and senile plaques in the brain of patients with dementia. The disease frequently starts with memory impairment, but is invariably followed by a progressive global cognitive impairment [8]. Vascular dementia is the second most common cause of dementia in the elderly after Alzheimer’s disease. Vascular dementia is defined as loss of cognitive function resulting from ischemic, hypoperfusive, or haemorrhagic brain lesions due to cerebrovascular disease or cardiovascular pathology. Diagnosis of vascular dementia requires cognitive impairment; vascular brain lesions, often predominantly subcortical, as demonstrated by brain imaging; a temporal link between stroke and dementia; and exclusion of other causes of dementia [9]. The combination of Alzheimer’s disease and vascular dementia pathological changes in the brains of older people are extremely common, making mixed dementia probably the most common type of dementia [10].

Alzheimer’s disease was first identified more than 100 years ago, but research into its symptoms, causes, risk factors and treatment has gained momentum only in the last 30 years. Although research has revealed a great deal about Alzheimer’s, the precise physiologic changes that trigger the development of Alzheimer’s disease largely remain unknown. The only exceptions are certain rare, inherited forms of the disease caused by known genetic mutations. Alzheimer’s disease affects people in different ways, but the most common symptom pattern begins with gradually worsening ability to remember new information. This occurs because disruption of brain cell function usually begins in brain regions involved in forming new memories. As damage spreads, individuals experience other difficulties. The following are warning signs of Alzheimer’s disease: memory loss that disrupts daily life; challenges in planning or solving problems; difficulty completing familiar tasks at home, at work or at leisure; confusion with time or place; trouble understanding visual images and spatial relationships; new problems with words in speaking or writing; misplacing things and losing the ability to retrace steps; decreased or poor judgment; withdrawal from work or social activities; and changes in mood and personality. As the disease progresses, the individual’s cognitive and functional abilities decline. In advanced Alzheimer’s disease, people need help with basic activities of daily living, such as bathing, dressing, eating and using the bathroom. Those in the final stages of the disease lose their ability to communicate, fail to recognize loved ones and become bed-bound and reliant on around-the-clock care. When an individual has difficulty moving because of Alzheimer’s disease, they are more vulnerable to infections, including pneumonia (infection of the lungs).


2. Occurrence of Alzheimer’s disease

The occurrence of a disease can be measured as proportion of people affected by the disease in a defined population at a specific time point (prevalence), or as number of new cases that occur during a specific time period in a population at risk for developing that disease (incidence). The prevalence reflects the public health burden of the disease, whereas the incidence indicates the risk of developing that disease. The prevalence is determined by both incidence and duration of the disease, and in certain circumstances, the prevalence may be estimated as incidence × average disease duration.

2.1. Prevalence

Based on the available epidemiological data, a group of experts estimated that 24.3 million people have dementia today, with 4.6 million new cases of dementia every year (one new case every 7 seconds). The number of people affected will double every 20 years to 81.1 million by 2040 [11]. Similar estimates have been reported previously [12]. Most people with dementia live in developing countries. China and its western Pacific neighbours have the highest number of people with dementia (6 million), followed by the European Union (5.0 million), USA (2.9 million), and India (1.5 million). The rates of increase in the number of dementia cases are not uniform across the world; numbers in developed countries are forecasted to increase by 100% between 2001 and 2040, but to increase by more than 300% in India, China, and other south Asian and western Pacific countries [11]. About 70% of these cases were attributed to Alzheimer’s disease [11, 13]. The pooled data of population-based studies in Europe suggests that the age-standardized prevalence in people 65+ years old was 6.4 % for dementia and 4.4 % for Alzheimer’s disease [14]. In the US, a study of a national representative sample of people aged >70 years yielded a prevalence for Alzheimer’s disease of 9.7 % [15].

Worldwide, the global prevalence of dementia was estimated to be 3.9 % in people aged 60+ years, with the regional prevalence being 1.6 % in Africa, 4.0 % in China and Western Pacific regions, 4.6 % in Latin America, 5.4 % in Western Europe, and 6.4 % in North America [11]. A meta-analysis including 18 studies from China during 1990-2010 showed prevalence of Alzheimer’s disease of 1.9% [16]. More than 25 million people in the world are currently affected by dementia, most suffering from Alzheimer’s disease, with around 5 million new cases occurring every year [11]. The number of people with dementia is anticipated to double every 20 years. Despite different inclusion criteria, several meta-analyses and nationwide surveys have yielded roughly similar age-specific prevalence of AD across regions (Figure 1) [17]. The age-specific prevalence of Alzheimer’s disease almost doubles every 5 years after aged 65. Among developed nations, approximately 1 in 10 older people aged ≥ 65 is affected by some degree of dementia, whereas more than one third of very old people aged ≥85 years may have dementia-related symptoms and signs [18, 19]. There is a similar pattern of dementia subtypes across the world, with Alzheimer’s disease and vascular dementia, the two most common forms of dementia, accounting for 50 % to 70 % and 15 % to 25 %, respectively, of all dementia cases.

Figure 1.

Age-specific prevalence of Alzheimer's disease (per 100 population) across continents and countries. *prevalence of all types of dementia [17].

Epidemiological research of dementia and AD in low- and middle-income countries has drawn much attention in recent years. A systematic review estimated that the overall prevalence of Alzheimer’s disease in developing countries was 3.4 % (95 % CI,1.6 % - 5.0 %) [20]. The prevalence of dementia (DSM-IV criteria) in people aged 65+ years in seven developing nations varied widely from less than 0.5 % to more than 6 %, which is substantially lower than in developed countries [21]. Indeed, the prevalence rates of dementia in India and rural Latin America were approximately a quarter of the rates in European countries. However, the prevalence of AD in persons 65+ years in urban areas of China was 3.5 %, and even higher (4.8 %) after post-hoc correction for negative screening errors [22], which is generally comparable with those from Western nations. Similar prevalence rates of dementia were also reported from the urban populations of Latin American nations such as Havana in Cuba (6.4 %) and São Paulo in Brazil (5.1 %) [20, 23, 24].

2.2. Incidence

The global annual incidence of dementia is around 7.5 per 1,000 persons [11]. The incidence rate of dementia increases exponentially with age, from approximately one per 1,000 person-year in people aged 60-64 years to more than 70 per 1,000 person-year in 90+ year-olds. The incidence rates of dementia across regions are quite similar in the younger-old (<75 years), but greater variations are seen among the older ages [25]. Slightly lower rates have been detected in the USA in comparison with Europe and Asia, and this is possibly due to differences in the study designs and the case ascertainment procedures. The pooled incidence rate of Alzheimer’s disease among people 65+ years of age in Europe was 19.4 per 1000 person-year [26]. The pooled data from two large-scale community-based studies of people aged ≥65 years in the US Seattle and Baltimore areas yielded an incidence rate for Alzheimer’s disease of 15.0 (male, 13.0; female, 16.9) per 1000 person-year [27, 28]. The incidence rate of Alzheimer’s disease increases almost exponentially with increasing age until 85 years of age (Figure 2) [17]. A consistently exponential increase, with advancing age in Alzheimer incidence suggests that Alzheimer’s disease is an inevitable consequence of aging, whereas a convergence to or a decline at certain age may suggest that very old people may have reduced vulnerability, owing perhaps to genetic or environmental factors. The Cache County Study further found that the incidence of AD increased with age, peaked, and then started to decline at extreme old ages for both men and women [29]. However, some meta-analyses and large-scale studies in Europe provided no evidence for the potential decline in the incidence of dementia and Alzheimer’s disease among the oldest-old age groups [26, 30, 31]. The apparent decline suggested in some studies may be an artifact of poor response rate and survival effect in these very old age groups. Several studies from Europe observed a higher incidence rate of Alzheimer’s disease among women than men, especially among the oldest-old age groups, whereas studies in North America found no significant gender difference [17].

Figure 2.

Age-specific incidence of Alzheimer's disease (per 1 000 person years) across continents and countries. *incidence of all types of dementia [17].

There appears to be some geographic variations in the incidence of Alzheimer’s disease. The pooled data of eight European studies suggested a geographical dissociation across Europe, with higher incidence rates being found among the oldest-old people of north-western countries than among southern countries [26]. The incidence rates of Alzheimer’s disease were reported to be slightly lower in North America than in Europe. Differences in methodology (e.g., differences in study design and procedure of case ascertainment), rather than real different regional distributions of the disease, may be partly responsible for the geographic variations. The study using identical methods in UK found no evidence of variation in dementia incidence among five areas in England and Wales [30]. Studies have confirmed that AD incidence in developing countries is generally lower than in North America and Europe. For example, the incidence rate of AD among people aged 65+ years was 7.7 per 1 000 person-year in Brazil and 3.2 per 1 000 person-year in India [20, 32].


3. Prognosis and impact

Dementia is one of the leading causes of death in older people. However, death certificates grossly underreport its cause, even when multiple underlying causes of death are taken into account. The community-based follow-up studies could provide reliable data on mortality. In the Swedish Kungsholmen Project of people aged 75 years or over, the mortality rate of dementia was 2.4 per 100 person-year; 70% of incident dementia cases died within five years following the diagnosis. In three years, more than 50% of the dementia cases reached the severe stage. In the Kungsholmen Project, the proportion of severe dementia among prevalent cases increased from 19% at baseline to 48% after three years, and to 78% after seven years. This progression is due to both cognitive and functional decline [33]. Dementia is strongly associated with disability as it has been found to be the major determinant of developing dependence and functional decline over three years. Approximately half of the persons who developed functional dependence in a three year period can attribute to dementia [34]. In industrialised countries, mental disease and cognitive impairment are the most prevalent disorders among older adults living in nursing homes or other institutions. However, institutionalisation of demented patients varies depending on age structure, urban or rural residence, and other cultural aspects. In a 75+ year old population, 70% of incident dementia cases died in the five years following the diagnosis, accounting for a mortality rate specific for dementia of 2.4 per 100 person-years. Dementia triples the risk of death [35]. The demands of healthcare and social service of the huge and rapidly growing numbers of dementia patients have a major economic impact at the societal level [36]. The worldwide direct costs for dementia in 2003 were estimated at 156 billion USD in the main scenario of a worldwide prevalence of 27.7 million demented persons. It is obvious that due to these costs and the expected increase in the number of elderly people in developing countries, the dementing conditions will present a great challenge [37,38].


4. Risk and protective factors

Alzheimer’s disease is multifactorial disorder that is determined by genetic and environmental factors as well as their interactions. Population-based prospective study is the major epidemiological approach to identifying influential factors for chronic multifactorial diseases such as dementia, in which the life-course approach should be taken into consideration. Age is the most powerful determinant of Alzheimer’s disease, and gene mutations contribute to a small proportion of all cases. The strong association of Alzheimer’s disease with increasing age may partially reflect the cumulative effect of different risk and protective factors over the lifespan, including the effect of complex interactions of genetic susceptibility, psychosocial factors, biological factors, and environmental exposures experienced over the lifespan. Evidence from epidemiological, neuroimaging, and neuropathological research, supports the role of genetic, vascular, and psychosocial factors in the development of Alzheimer’s disease, whereas evidence for the etiologic role of dietary or nutritional factors, occupational exposures, and inflammation is less clear [39].

4.1. Genetic factors

Mutations in amyloid precursor protein, presenilin-1, and presenilin-2 genes can cause early-onset familial Alzheimer’s disease that account for no more than 5% of all cases. The majority of AD cases are sporadic, with considerable heterogeneity in their risk profiles and neuropathological features.

4.1.1. Apolipoprotein E ε4 (APOE ε4)

The APOE ε4 allele is the only established susceptibility gene for both early- and late-onset Alzheimer’s disease, and is a susceptibility gene, being neither necessary nor sufficient for the development of Alzheimer’s disease. APOE ε4 is one of three common forms (ε2, ε3 and ε4) of the APOE gene, which provides the blue print for a protein that carries cholesterol in the bloodstream. Everyone inherits one form of the APOE gene from each parent. Those who inherit one APOE ε4 gene have increased risk of developing Alzheimer’s disease and of developing it at an earlier age than those who inherit the ε2 or ε3 forms of the APOE gene [40]. Those who inherit two APOE-ε4 genes have an even higher risk. Unlike inheriting a known genetic mutation for Alzheimer’s disease, inheriting one or two copies of this form of the APOE gene does not guarantee that an individual will develop Alzheimer’s disease. The risk effect of the APOE ε4 allele decreases with increasing age, and after age 75, 15–20% of Alzheimer’s cases are attributable to APOE genotype [41]. Several other genes have been examined as possible candidates, but the reports are sporadic, and the results are inconsistent [42].

However, not all (4-carriers develop dementia. Studies have demonstrated that high education, active leisure activities, or maintaining vascular health seems to reduce the risk of dementia related to APOE ε4 [40, 41]. The ε4-carriers with these characteristics appear to have similar dementia-free survival time to non ε4-carriers. Further, the obese related FTO gene may interact with APOE ε4 to increase the risk of Alzheimer’s disease [44].

4.1.2. Family history

Individuals who have a parent, brother or sister with Alzheimer’s are more likely to develop the disease than those who do not have a first-degree relative with Alzheimer’s [45-47]. Those who have more than one first-degree relative with Alzheimer’s disease are at even higher risk of developing the disease [48]. When diseases run in families, heredity (genetics), shared environmental and /or lifestyle factors or both may play a role.

4.2. Biological risk factors

Increasing age is a well-established risk factor for Alzheimer’s disease. The incidence of Alzheimer’s disease almost doubles with every 5 years of age [49, 50]. Female sex is often associated with an increased risk of AD, especially at the oldest-old age [25]. Men seem to be at greater risk for vascular dementia than women [51].

4.3. Vascular disorders and risk factors

A number of vascular risk factors and disorders have been linked to Alzheimer’s disease, but some factors may have a differential association with the risk of Alzheimer’s disease depending on the age when the exposure is assessed.

4.3.1. Blood pressure

Several studies have consistently reported an association between midlife high blood pressure and increased risk of dementia and Alzheimer's disease [52, 53]. Hypertension has been linked to neurodegenerative markers in the brain, suggesting that long-term high blood pressure may play a causal role in the neurodegenerative process itself or by causing brain atrophy. In very old people, the deleterious effect of high blood pressure is less evident, whereas low blood pressure seems to be predictive of dementia and Alzheimer’s disease. As dementia has a long latent period, low blood pressure may be a sign of impending illness [54], which was confirmed by the longitudinal data from the Kungsholmen Project, suggesting the involvement of late life low blood pressure and cerebral hypo-perfusion in the development of dementia and Alzheimer’s disease [55]. All these findings suggest that the relation of blood pressure to dementia may be age-dependent [25].

Recent follow-up studies have suggested that the protective effect of antihypertensive therapy on dementia and AD may depend on the duration of treatment and the age when people take the medications; the more evident efficacy was seen among young-old people (i.e., <75 years) and those with long-term treatment [56, 57]. Evidence from clinical trials of antihypertensive therapy and dementia is summarized in the section on intervention trials towards primary prevention. Antihypertensive treatment may protect against dementia and AD by postponing atherosclerotic process, reducing the number of cerebrovascular lesions, and improving cerebral perfusion [52]. It has also been suggested that some antihypertensive agents (e.g., calcium-channel antagonists) may have neuroprotective effects. The recent neuropathological study found substantially less Alzheimer neuropathological changes (i.e., neuritic plaque and neurofibrillary tangle densities) in the medicated hypertension group than non-hypertensive group, which may reflect a salutary effect of antihypertensive therapy against Alzheimer’s disease-associated neuropathology [57].

4.3.2. Cardiovascular disease

A healthy heart helps ensure that enough blood is pumped through blood vessels to the brain. The follow-up data of the Cardiovascular Health Study showed that cardiovascular disease was associated with an increased risk of Alzheimer’s disease, especially in people with peripheral arterial disease [58], suggesting that extensive peripheral atherosclerosis is a risk factor for Alzheimer’s disease. Other cardiovascular diseases, such as heart failure and atrial fibrillation, have been independently related to increased risk of dementia. In the Kungsholmen Project, heart failure was associated with a more than 80% increased risk of dementia and Alzheimer’s disease [59].

4.3.3. Cerebrovascular disease

Cerebrovascular changes such as haemorrhagic infarcts, small and large ischemic cortical infarcts, vasculo-pathie, and white matter changes all increase the risk of dementia [13]. Systematic reviews of population-based studies reveal an approximately two- to four-fold increased risk of incident dementia associated with clinical stroke (post-stroke dementia). Multiple cerebral infarcts, recurrent and strategic strokes are main risk factors for post-stroke dementia. Silent stroke and white matter lesions detected on neuroimaging are associated with increased risk of dementia and cognitive decline. Spontaneous cerebral emboli were related to both AD and VaD. Some studies reported an association of stroke with Alzheimer’s disease and cognitive decline [60]. Cerebral vascular lesions may interact with neurodegenerative lesions to produce a dementia syndrome in individuals not having sufficient neurodegenerative damages to express dementia [25]. Neuropathological studies suggested that cerebrovascular lesions, atherosclerosis, and neurodegenerative changes in the brain often coexist, and may be coincident processes converging to cause additive damage to the aging brain and to promote clinical expression of the dementia syndrome [61].

4.3.4. Diabetes mellitus

A potential link between diabetes and cognitive impairment was first reported more than 80 years ago. The association of diabetes with these cognitive changes is now well established [62]. There is substantial evidence suggesting that type 2 diabetes is associated with cognitive impairment involving both memory and executive function [63-65]. Several large longitudinal population-based studies have also shown that the rate of cognitive decline is accelerated in elderly people with type 2 diabetes [66]. An increased risk of not only vascular dementia but also neurodegenerative type dementia among persons with diabetes has been reported in several longitudinal studies [67-70], and the risk effect was confirmed by a systematic review [71]. Midlife diabetes or a longer duration of diabetes may play a crucial role in dementia and Alzheimer’s disease [68, 72]. Overall, diabetes leads to a 20-70% greater decline in cognitive performance, and a 60% higher risk of dementia [73]. In addition, borderline or prediabetes or impaired glucose tolerance, is also linked to an increased risk of dementia and Alzheimer’s disease in very old people [74].

4.3.5. Overweight and obesity

Similar to hypertension, recent studies suggested a lifespan-dependent relation of obesity with dementia [75, 76]. A higher body mass index (BMI) at middle age was related to an increased risk of dementia in late life [77, 78]. A greater decline in BMI approximately 10 years prior to dementia onset was detected, which is in line with the other studies suggesting an association of accelerated BMI decline with Alzheimer’s disease [79, 80]. Low BMI in late life and weight loss may be related to high risk of dementia and Alzheimer’s disease [81], but low BMI and weight loss can be interpreted as markers of preclinical Alzheimer’s disease, especially when measured less than 10 years prior to clinical diagnosis [25]. In line with these findings, several follow-up studies of older people suggested that accelerated decline in BMI was associated with future development of Alzheimer’s disease [79, 82, 83]. Low BMI in late life was related to a higher risk for Alzheimer’s disease over a subsequent 5- to 6-year period [81]. Thus, late-life low BMI and weight loss can be interpreted as markers for preclinical Alzheimer’s disease, particularly when measured just a few years prior to clinical diagnosis of the disease [17].

4.3.6. Hyperlipidaemia

An association of elevated cholesterol at middle life with increased risk of late-life Alzheimer’s disease was reported in some studies [53]. Controversial findings have also been reported on the relation of cholesterol in late life to dementia risk. Some cohort studies found no association or even an inverse association of total cholesterol with dementia risk [84]. A study showed a decline in total cholesterol at least 15 years before dementia onset [85]. Recently, a bidirectional cholesterol-cognition relationship has been reported. High midlife cholesterol was associated with poorer late-life cognition, but decreasing cholesterol after midlife may reflect poorer cognitive status [86].

4.3.7. The metabolic syndrome

Instead of exploring the effect of its subcomponents, several studies have assessed the relationship between metabolic syndrome as a whole and the risk of Alzheimer’s disease or cognitive decline. A clustering of interrelated metabolic risk factors such as diabetes, obesity, hypertension and dyslipidaemia has received increasing attention in the past few years. Several components of the metabolic syndrome have been individually related to cognitive outcomes. A prospective study found that the metabolic syndrome contributed to cognitive decline [87]. But this finding was not confirmed in a population of the oldest old. The concept of the metabolic syndrome may be less valid in this age group [88]. Finally, two studies showed that metabolic syndrome was associated with an increased risk of Alzheimer’s disease [89, 90].

4.3.8. Alcohol consumption

Excessive alcohol intake can cause alcoholic dementia and may increase the risk of vascular dementia. Heavier alcohol intake at middle age was associated with increased risk of late-life dementia [91]. By contrast, increasing evidence suggests that light to moderate alcohol consumption may be associated with a reduced risk of dementia and cognitive decline [92], a similar effect as observed for cardiovascular disease [25]. In a meta-analysis of 15 prospective studies on the effect of alcohol on dementia risk, light to moderate alcohol consumption was associated with a reduction in the risk of Alzheimer’s disease and dementia [93]. However, the role of moderate alcohol consumption in dementia still remains controversial because the inverse association may be due to information bias, the confounding of healthy lifestyles and high socioeconomic status, different approaches in assessments of alcohol consumption, or outcome misclassification.

4.3.9. Cigarette smoking

The relationship between smoking and cognitive decline remains uncertain. Case-control studies have largely suggested that smoking lowers the risk of Alzheimer’s disease [13]. Some prospective studies have found an increased risk of Alzheimer’s disease associated with smoking [94]. A meta-analysis that examined the association between smoking and Alzheimer’s disease while accounting for tobacco-industry affiliation found that the combined results of 18 cross-sectional studies without industry affiliations yielded no association [95]. Analysis of 14 cohort studies without tobacco-industry affiliations yielded a significant increase in the risk of Alzheimer’s disease [13]. In the Kungsholmen Project, smoking affected survival in Alzheimer’s disease cases more than in non-demented subjects, and the protective effect of smoking on the Alzheimer’s disease was no longer present when incident Alzheimer’s cases were studied [7] suggesting that previously reported association of cigarette smoking with low prevalence of dementia was probably due to survival bias.

4.3.10. Diet and nutrients

Diets high in fish, fruits and vegetables are high in anti-oxidants and polyunsaturated fatty acids (PUFAs). In some observational studies, high or supplementary intake of vitamins C, E, B6, B12, and folate has been related to a decreased risk of Alzheimer’s disease [96, 97]. Indeed, low levels of B12 and folate were found to be related to an increased risk of Alzheimer’s disease in a study from the Kungsholmen Project [98]. Investigations on the effect of dietary PUFAs on the risk of cognitive dysfunction proved inconclusive. Several studies showed that the consumption of PUFAs led to reduction in the risk of Alzheimer’s disease and dementia, mild cognitive impairment [99]. Population-based studies suggested that moderate to high intake of unsaturated fats at midlife is protective, whereas a moderate intake of saturated fats may increase the risk of dementia and Alzheimer’s disease [100, 101], especially among APOE ε4 carriers [102, 103]. Fatty acids may affect dementia through various mechanisms such as atherosclerosis and inflammation. Adherence to ‘Mediterranean diet’ (higher intake of fish, fruits, and vegetables rich in antioxidants) was associated with a reduced risk of Alzheimer’s disease independent of vascular pathways [104].

4.4. Psychosocial factors

Psychological factors include social economic status, education attainment in early life, and work complexity in adult-life and leisure activities. Evidence from epidemiological research has been accumulating that some psychosocial factors and healthy lifestyle may postpone the onset of dementia, possibly by enhancing cognitive reserve.

4.4.1. Social economic status

A number of studies have found that higher socioeconomic status (SES) is associated with a reduced risk of developing Alzheimer’s disease [105-107]. In most of these studies, SES was assessed based on occupational attainment, current income to reflect socioeconomic level in adulthood, or educational attainment. Findings from a prospective study, however, suggested that early life socioeconomic status assessed at the household or community level was related to level of cognition in late life but not to rate of cognitive decline or risk of Alzheimer’s disease [47].

4.4.2. High education

Numerous longitudinal studies have consistently shown that a higher educational achievement in early life is associated with a decreased incidence of dementia, and of Alzheimer’s disease in particular. Low dementia prevalence among highly educated persons has been reported by numerous surveys. Educational attainment and lifespan mental activity associated with childhood education may reduce the risk of dementia [25]. The cogntive reserve hypothesis has been proposed to interpret this association such that education could enhance neural and cognitive reserve that may provide compensatory mechanisms to cope with degenerative pathological changes in the brain, and therefore delay onset of the dementia syndrome [17]. Alternatively, educational achievement may be a surrogate or an indicator of intelligent quotient, early life living environments, and occupational toxic exposure experienced over adulthood [108].

4.4.3. Physical activity

Basic science and observational evidence on humans strongly supports the hypothesis that increased physical activity prevents the onset of dementia. Regular exercise, even low-intensity activity such as walking, has been associated with reduced risk of dementia and cognitive decline [109-111]. In the Kungsholmen Project, the component of physical activity presenting in various leisure activities, rather than sports and any specific physical exercise, was related to a decreased dementia risk [110]. A strong protective effect of regular physical activity in middle age against the development of dementia and Alzheimer’s disease in late life was reported, especially for persons with the APOE ε4 allele [112]. As it may take years to achieve high levels of physical fitness, brief periods of exercise training may not have substantial benefits on cognitive processes, but could still be detectable in the subsets of cognitive domains that are more sensitive to the age related decrements. Physical activity is important not only in promoting general and vascular health, but also in promoting brain plasticity, and it may also affect several gene transcripts and neurotropic factors that are relevant for the maintenance of cognitive functions. There is now increasing amounts of trial evidence to support this hypothesis in terms of cognitive benefits in healthy older adults as well as in people at risk for dementia. However, to date there are no RCTs confirm that increased physical activity prevents dementia.

4.4.4. Mentally stimulating activity

Various types of mentally demanding activities have been examined in relation to dementia and AD, including knitting, gardening, dancing, playing board games and musical instruments, reading, social and cultural activities, and watching specific television programs, which often showed a protective effect [113]. Due to the cultural and individual differences in choosing specific activities, some researchers summarize mentally stimulating activities into a composite score, which showed that a cognitive activity score involving participation in seven common activities with information processing as a central component was associated with a reduced risk of AD, even after controlling for APOE ε4 allele, medical conditions, and depressive symptoms [114, 115]. The Swedish Twin Study showed that greater complexity of work, and particularly complex work with people, may reduce the risk of Alzheimer’s disease [116]. The Canadian Study of Health and Aging found that high complexity of work appeared to be associated with a reduced risk of dementia, but mostly for vascular dementia [117]. In supporting of these findings, the recent neuroimaging study suggested that a high level of complex mental activity across the lifespan was correlated with a reduced rate of hippocampal atrophy [118].

4.4.5. Social network and social engagement

A poor social network or social disengagement in late life was associated with an elevated risk of dementia. Evidence from longitudinal observational studies suggests that a poor social network or social disengagement is associated with cognitive decline and dementia [119, 120]. The risk for dementia and AD was also increased in older people with increasing social isolation and less frequent and unsatisfactory contacts with relatives and friends. Furthermore, low social engagement in late life and a decline in social engagement from middle age to late life were associated with a doubly increased risk of developing dementia and AD in late life. Rich social networks and high social engagement imply better social support, leading to better access to resources and material goods [123]. Rich and large social networks also provide affective and intellectual stimulation that could influence cognitive function and different health outcomes through behavioural, psychological, and physiological pathways [122]. Finally, a recent study suggested that low neuroticism in combination with high extraversion was the personality trait associated with the lowest dementia risk, and among socially isolated individuals even low neuroticism alone seemed to decrease the risk of dementia [121].

4.4.6. Depression

Recent evidence suggests a strong relationship between depression and Alzheimer's disease. A lifetime history of major depression has been considered as a risk factor for later development of Alzheimer's disease [124, 125]. The presence of depressive symptoms can affect the conversion of mild cognitive impairment to Alzheimer's disease. Neuronal plaques and neurofibrillary tangles, the two major hallmarks of Alzheimer's disease brain, are more pronounced in the brains of Alzheimer's disease patients with comorbid depression as compared with Alzheimer's disease patients without depression. On the other hand, neurodegenerative phenomena have been observed in different brain regions of patients with a history of depression. Recent evidence suggests that molecular mechanisms and cascades that underlie the pathogenesis of major depression, such as chronic inflammation and hyper-activation of hypothalamic–pituitary–adrenal (HPA) axis, are also involved in the pathogenesis of Alzheimer's disease [125]. A recent study has shown that depression increased the risk of dementia among patients with diabetes [126].

4.5. Other factors

4.5.1. Inflammation

Inflammation is known to be involved in the atherosclerotic process. Thus, serum inflammatory makers may be associated with dementia. Some cohort studies found such an association, and C-reactive protein may be the most promising in predicting dementia risk [127]. In addition, long-term use of non-steroidal anti-inflammatory drugs was suggested to be associated with a lower risk of AD [25].

4.5.2. Hormone replacement therapy

Hormone replacement therapy in postmenopausal women has been frequently reported to be associated with a lower risk of AD. An association between hormone replacement therapy and a reduced risk of dementia and Alzheimer’s disease among postmenopausal women had been frequently reported in numerous observational studies until 2004 when, instead of a protective effect, a significantly increased risk of dementia associated with estrogenic therapy was found in the Women's Health Study [128].

4.5.3. Occupational exposures

Manual work involving goods production has been associated with an increased risk of AD and dementia. Occupation and occupational exposures (e.g., electromagnetic fields and heavy metals) may play a role in dementia and Alzheimer’s disease [129, 130]. Data from the Kungsholmen Project showed that manual work involving goods production was associated with an increased risk of dementia and Alzheimer’s disease [130], and specifically a risk effect was detected with electromagnetic exposure [129]. Occupational exposure to extremely-low-frequency electromagnetic fields (ELF-EMF) has been related to an increased risk of dementia and AD in a number of follow-up studies [129, 131]. The meta-analysis of epidemiological evidence suggests an association between occupational exposure to ELF-EMF and AD [132].

4.5.4. Head trauma and traumatic brain injury

For many years, head trauma has been suggested as a possible risk factor for Alzheimer’s disease, and it has been extensively investigated in several studies, but this possible association still remains controversial. Moderate head injuries are associated with twice the risk of developing Alzheimer’s compared with no head injuries, and severe head injuries are associated with 4.5 times the risk [133, 134]. Moderate head injury is defined as a head injury resulting in loss of consciousness or post-traumatic amnesia lasting more than 30 minutes; if either of these lasts more than 24 hours, the injury is considered severe. These increased risks have not been shown for individuals experiencing mild head injury or any number of common mishaps, such as bumping one’s head while exiting a car. Groups that experienced repeated head injuries, such as boxers, football players and combat veterans, may be at increased risk of dementia, late-life cognitive impairment and evidence of tau tangles (a hallmark of Alzheimer’s) at autopsy [135-138]. Additional research is needed to better understand the association between brain injury and increased risk of Alzheimer’s disease.


5. Summary of evidence from systematic review

Meta-analyses and systematic reviews have provided robust evidence that cognitive reserve (a concept combining the benefits of education, occupation, and mental activities) [139], physical activity and exercise [140, 141], midlife obesity [142], alcohol intake [93], and smoking [142] are the most important modifiable risk factors for Alzheimer's disease. There is insufficient overall evidence from epidemiological studies to support any association between dietary or supplementary antioxidant or B vitamins and altered risk of incident dementia [143, 144]. Data from several independent time points from a large Swedish epidemiological study suggest that better social networks and social activities might be associated with reduced incidence of Alzheimer's disease [119], but this has not been examined systematically in other large epidemiological cohorts [61].

Many treatable medical conditions have also been associated with an increased risk of Alzheimer's disease, including stroke [145], diabetes [146], midlife hypertension [52], and midlife hypercholesterolemia [147, 148]. Blood pressure and cholesterol both seem to be reduced in late life and in the prodromal to Alzheimer's disease; thus, the difference between midlife and late life is an important distinction. There is probably an important relation between some of these conditions and the lifestyle factors mentioned previously, and interventions to promote healthy living will probably reduce the incidence of diabetes and stroke as well as having other, more direct, effects on dementia. There is limited evidence about the potential effect of management of diabetes or stroke on the risk of subsequent dementia, more intervention trials on this topic are needed (Table 1) [61,149].

Less than two decades have passed since the first incidence data for Alzheimer's disease and other dementias were reported, during which there have been many achievements in the understanding of risk and protective factors of Alzheimer’s disease. Accumulated evidence from epidemiological research strongly supports a role for lifestyle and cardiovascular risk factors in the pathogenesis and development of dementia. However, none of these factors has been proven to have a causal relation specifically with Alzheimer’s disease. Indeed, this topic is further complicated by the fact that the traditional diagnosis of dementia subtypes has been challenged by population-based neuropathological and neuroimaging studies. Research has shown a range of dementia-associated brain abnormalities from pure vascular lesions at one end to pure Alzheimer's pathologies at the other, with most dementia cases being attributable to both vascular disease and neurodegeneration.

Factors Systematic review Results
Overweight and obesity Meta-analysis of ten studies. Sixteen articles on 15 prospective studies with 3.2-36 years follow-up Overweight: Dementia RR 1.26 (95% CI 1.10–1.44); Alzheimer's disease 1.35 (95% CI 1·19–1.54)
Obesity: Dementia RR 1.64 (95% CI 1.34-2.00); Alzheimer’s disease RR 2.04 (95% CI 1.59-2.62)
Smoking Meta-analysis of four prospective studies with 2–25 years follow-up in over 17 000 people. In the four studies the dementia ORs were 3·17 (95% CI 1.37–7.35), 1.42 (1.07–1.89), 1.60 (1.00–2.57), and 1.63 (1.00–2.67) Dementia RR 2.2 (95% CI 1.3–3.6)
Physical activity 13 prospective studies focusing on Alzheimer's disease, dementia, or both, with at least 150 000 participants Dementia RR 0.72 (95% CI 0.60–0.86); Alzheimer's disease 0.55 (95% CI 0.36–0.84)
Cognitive reserve (intelligence, occupation, and education) 22 prospective studies with at least 29 000 participants followed up for a median of 7.1 years Dementia OR 0.54 (95% CI 0.49–0.59)
Alcohol 15 longitudinal studies with 2–8 years follow-up and at least 14 000 participants Dementia RR 0.74 (95% CI 0.61–0.91); Alzheimer's disease 0.72 (0.61–0.86)
Medical conditions
Midlife hypertension At least 15 years follow-up in most studies, with at least 16 000 participants Four of five longitudinal studies focusing on midlife hypertension suggested that it is a significant risk factor for incident dementia (RR 1.24–2.8 in different studies) The biggest differences were reported in studies using 160/95 mm Hg as the threshold for hypertension
Stroke 16 studies with at least 25 000 participants, mainly included patients aged 65 years and over 12 of 16 studies showed significant association between stroke and incident dementia, with overall doubling of incidence
Diabetes 15 prospective cohort studies Dementia RR 1.47 (95% CI 1.25–1.73); Alzheimer's disease RR 1.39 (95% CI 1.16–1.66)
Midlife hypercholesterolemia 18 studies, but only five assessed high cholesterol specifically in midlife. All five midlife studies had over 15 years follow-up and a total of over 15 000 participants Four of five longitudinal studies in midlife suggested a significant positive association between high total cholesterol and incident dementia. For overall difference the RR was 1·4–3·1
Intervention studies
Hypertension 12 091 participants between the three trials (SHEP, SYST-EUR, and SCOPE) with mean follow-up of 3·3 years. Only SYST-EUR reported significant benefit OR 0.89 (95% CI 0.69–1.16) for incident dementia
Statins for prevention of dementia 26 340 participants between the two trials (PROSPER and HPS), with follow-up of 3·2 and 5 years. Cognition was measured with different instruments at different timepoints Neither of the two trials reported significant benefit of statin therapy
Vitamins B12 or folate Four trials in older people without existing cognitive impairment Three trials showed no benefit. One trial (the only that selected participants based on increased homocysteine) reported benefit with respect to global function

Table 1.

Meta-analyses or systematic reviews of risk factors for dementia and Alzheimer's disease [61,149]

RR=relative risk. OR=odds ratio. SHEP=Systolic Hypertension in the Elderly Program. SYST-EUR=Systolic Hypertension in Europe. SCOPE=Study on Cognition and Prognosis in the Elderly. PROSPER=PROspective Study of Pravastatin in the Elderly at Risk. HPS=Heart Protection Study.

Population studies have identified many factors that could be important in reducing the risk of dementia, including factors that identify people at risk for dementia (vascular risk factors, depressive symptoms) and factors that may reduce the risk of dementia (cognitive, physical, and social activity, a diet rich in antioxidants and polyunsaturated fatty acids, vascular risk factor control). While early interventional studies have been less conclusive, future trials should continue to examine the effect of risk factor modification on cognitive outcomes. In particular, interventions that combine a number of factors, such as healthy nutrition along with cognitive, social, and physical activity, should be investigated. In the most optimistic view, dementia could be delayed or even prevented by these interventions. At worst, people will improve their overall health, especially their cardiovascular health, and enjoy a more cognitively and socially engaging life.

5.1. Intervention strategies against Alzheimer’s disease

Despite the specific challenges posed by neurological disorders, such as Alzheimer’s disease and other dementias, interventions need to be implemented to verify findings from the many population-based observational studies, which suggest that preventive and therapeutic interventions have great potential [150].

5.1.1. Vascular factors and related disorders

Most vascular risk factors and related disorders are modifiable or treatable that can serve as targets in the development of primary preventative strategies against dementia. For example, antihypertensive therapy has been shown to reduce the risk of dementia in observational studies, and this finding was partly confirmed by clinical trials. Furthermore, studies have confirmed that obesity and diabetes can be prevented by changing dietary habits and lifestyles, and that health education may help quit smoking. Finally, preventing recurrent cerebrovascular disease and maintaining sufficient cerebral blood perfusion seems to be critical for postponing expression of the dementia syndrome in older people. Thus, controlling high blood pressure and obesity, especially from middle age, and preventing diabetes and recurrent stroke could be the primary preventive measures against late-life dementia.

5.1.2. Intervention towards psychosocial factors and lifestyles

High educational achievements in early life can provide cognitive reserve that benefits the whole life in terms of cognitive health and delaying the onset of late-life dementia. Extensive social networks and active engagements in intellectually stimulating activities such as reading, doing crosswords, and playing board games may significantly lower the risk of dementia by providing cognitive reserve or by reducing psychosocial stress. It is likely that mentally and socially integrated lifestyles could postpone the onset of dementia [119]. Regular physical exercise may reduce the risk of the dementias resulting from cerebral atherosclerosis. Leisure activities with all three components of physical, mental, and social activities may have the most beneficial effect on dementia prevention. Many of the risk factors for dementia, such as hypertension, diabetes, and obesity, may be modified by diet. In addition, a diet high in antioxidants may reduce inflammation, which is associated with the risk of dementia. Thus, it is reasonable to suggest that the risk of dementia itself could be modified by diet. The treatment of depression also seems to improve cognitive function in people who are depressed. Taking together, the most promising strategy for the primary prevention of dementia may be to encourage people implementing multiple preventative measures throughout the life course, including high educational attainment in childhood and early adulthood, an active control of vascular factors (e.g., smoking) and disorders (e.g., hypertension and diabetes) in adulthood, and maintenance of mentally, physically, and socially active lifestyles during middle age and later in life.


6. Conclusions

Alzheimer’s disease is a major cause of functional dependence, institutionalisation, and mortality among elderly people. Population-based studies have made a great contribution to our knowledge of Alzheimer’s disease. Although many aspects of Alzheimer’s disease are still unclear, we are now able to make more accurate diagnoses than before, and the pattern of dementia distribution has been sufficiently described to guide the planning of medical and social services. Epidemiological studies have shown that vascular risk factors in middle age and later in life significantly contribute to the development and progression of the dementia syndrome, whereas extensive social network and active engagement in social, physical, and mental activities may delay the onset of the dementing disorders. Hence, one of the promising strategies to deal with the tremendous challenge from the epidemic of dementia is to implement appropriate intervention measures from a life-course perspective. Achieving high education in early life and engaging mentally stimulating activity over adulthood to enhance cognitive reserve, and maintaining vascular health by adopting healthy lifestyles and optimally controlling vascular diseases to reduce the burden of vascular lesions in the brain. These preventive measures will enable people to maintain cognitive ability in late life, even though they may have developed a high load of Alzheimer pathologies in their brain.



Research grants were received from the Swedish council for working life and social research, the Swedish Research Council in Medicine and the Swedish Brain Power. This study was also supported in part by funds from the Loo and Hans Ostermans Foundation and the Foundation for Geriatric Diseases at Karolinska Institutet, the Gamla Tjänarinnor Foundation, Demensfonden and the Bertil Stohnes Foundation.


  1. 1. From the Centers for Disease Control and Prevention. Public health and aging: trends in aging--United States and worldwide. JAMA 2003;289(11):1371-1373.
  2. 2. Kinsella K, Velkoff VA. The demographics of aging. Aging Clin Exp Res 2002;14(3):159-169.
  3. 3. Lunenfeld B. An Aging World - demographics and challenges. Gynecol Endocrinol 2008;24(1):1-3.
  4. 4. Bennett DA. Editorial comment on 'Prevalence of dementia in the United States: the aging, demographics, and memory study' by Plassman et al. Neuroepidemiology 2007;29(1-2):133-135.
  5. 5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (DSM-III-R). Washington, DC: American Psychiatric Association; 1987.
  6. 6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
  7. 7. Fratiglioni L, Winblad B, von Strauss E. Prevention of Alzheimer's disease and dementia. Major findings from the Kungsholmen Project. Physiol Behav 2007;92(1-2):98-104.
  8. 8. Harvey R, Fox N, Rossor M. Dementia Handbook. London: Martin Dunitz; 1999.
  9. 9. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 2003;51(5 Suppl Dementia):S296-304.
  10. 10. Korczyn AD, Vakhapova V. The prevention of the dementia epidemic. J Neurol Sci 2007;257(1-2):2-4.
  11. 11. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112-2117.
  12. 12. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17(2):63-67.
  13. 13. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7(3):137-152.
  14. 14. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S4-9.
  15. 15. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007;29(1-2):125-132.
  16. 16. Zhang Y, Xu Y, Nie H, Lei T, Wu Y, Zhang L, et al. Prevalence of dementia and major dementia subtypes in the Chinese populations: A meta-analysis of dementia prevalence surveys, 1980-2010. J Clin Neurosci 2012;19(10):1333-1337.
  17. 17. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11(2):111-128.
  18. 18. Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ study. Neurology 2008;71(5):337-343.
  19. 19. von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurology 1999;56(5):587-592.
  20. 20. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008;7(9):812-826.
  21. 21. Llibre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, et al. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet 2008;372(9637):464-474.
  22. 22. Zhang ZX, Zahner GE, Roman GC, Liu J, Hong Z, Qu QM, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Archives of neurology 2005;62(3):447-453.
  23. 23. Llibre Rodriguez J, Valhuerdi A, Sanchez, II, Reyna C, Guerra MA, Copeland JR, et al. The prevalence, correlates and impact of dementia in Cuba. A 10/66 group population-based survey. Neuroepidemiology 2008;31(4):243-251.
  24. 24. Scazufca M, Menezes PR, Vallada HP, Crepaldi AL, Pastor-Valero M, Coutinho LM, et al. High prevalence of dementia among older adults from poor socioeconomic backgrounds in Sao Paulo, Brazil. Int Psychogeriatr 2008;20(2):394-405.
  25. 25. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007;20(4):380-385.
  26. 26. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S10-15.
  27. 27. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000;54(11):2072-2077.
  28. 28. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59(11):1737-1746.
  29. 29. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology 2002;58(2):209-218.
  30. 30. Matthews F, Brayne C. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS Med 2005;2(8):e193.
  31. 31. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Incidence and etiology of dementia in a large elderly Italian population. Neurology 2005;64(9):1525-1530.
  32. 32. Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 2001;57(6):985-989.
  33. 33. Aguero-Torres H, Qiu C, Winblad B, Fratiglioni L. Dementing disorders in the elderly: evolution of disease severity over 7 years. Alzheimer Dis Assoc Disord 2002;16(4):221-227.
  34. 34. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von Strauss E, Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health 1998;88(10):1452-1456.
  35. 35. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999;52(8):737-743.
  36. 36. Cotter VT. The burden of dementia. Am J Manag Care 2007;13 Suppl 8:S193-197.
  37. 37. Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006;21(3):175-181.
  38. 38. Qiu C. Epidemiological findings of vascular risk factors in Alzheimer's disease: implications for therapeutic and preventive intervention. Expert Rev Neurother 2011;11(11):1593-1607.
  39. 39. Qiu C, Kivipelto M, Fratiglioni L. Preventing Alzheimer disease and cognitive decline. Ann Inter Med 2011;154(3):211; author reply 212-213.
  40. 40. Ferrari C, Xu WL, Wang HX, Winblad B, Sorbi S, Qiu C, et al. How can elderly apolipoprotein E epsilon4 carriers remain free from dementia? Neurobiol Aging 2012.
  41. 41. Qiu C, Kivipelto M, Aguero-Torres H, Winblad B, Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psychiatry 2004;75(6):828-833.
  42. 42. D'Introno A, Solfrizzi V, Colacicco AM, Capurso C, Amodio M, Todarello O, et al. Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease. Neurobiol Aging 2006;27(11):1537-1553.
  43. 43. Wang HX, Gustafson DR, Kivipelto M, Pedersen NL, Skoog I, Windblad B, et al. Education halves the risk of dementia due to apolipoprotein epsilon4 allele: a collaborative study from the Swedish Brain Power initiative. Neurobiol Aging 2012;33(5):1007 e1001-1007.
  44. 44. Keller L, Xu W, Wang HX, Winblad B, Fratiglioni L, Graff C. The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer's disease risk: a prospective cohort study. J Alzheimers Dis 2011;23(3):461-469.
  45. 45. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002;287(3):329-336.
  46. 46. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Ann Neurol 1993;33(3):258-266.
  47. 47. Wilson RS, Scherr PA, Hoganson G, Bienias JL, Evans DA, Bennett DA. Early life socioeconomic status and late life risk of Alzheimer's disease. Neuroepidemiology 2005;25(1):8-14.
  48. 48. Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Becker R, Burke J, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 1996;46(3):641-650.
  49. 49. Fratiglioni L, Rocca W. Epidemiology of dementia. In: Handbook of Neuropsychology (2nd Edition), Boller F and Cappa SF, eds Elsevier Science B.V.; 2001.
  50. 50. McVeigh C, Passmore P. Vascular dementia: prevention and treatment. Clin Interv Aging 2006;1(3):229-235.
  51. 51. Nelson NW. Differential diagnosis of Alzheimer's dementia and vascular dementia. Dis Mon 2007;53(3):148-151.
  52. 52. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4(8):487-499.
  53. 53. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64(2):277-281.
  54. 54. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005;57(6):789-794.
  55. 55. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 2003;60(2):223-228.
  56. 56. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006;37(5):1165-1170.
  57. 57. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology 2009;72(20):1727-1734.
  58. 58. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005;53(7):1101-1107.
  59. 59. Qiu CX, Winblad, B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 2006;166:1003-1008.
  60. 60. Purandare N, Burns A, Daly KJ, Hardicre J, Morris J, Macfarlane G, et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study. BMJ 2006;332(7550):1119-1124.
  61. 61. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377(9770):1019-1031.
  62. 62. Arvanitakis Z, Wilson RS, Bennett DA. Diabetes mellitus, dementia, and cognitive function in older persons. J Nutr Health Aging 2006;10(4):287-291.
  63. 63. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. Diabetologia 2005;48(12):2460-2469.
  64. 64. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007;64(4):570-575.
  65. 65. Arvanitakis Z, Wilson RS, Li Y, Aggarwal NT, Bennett DA. Diabetes and function in different cognitive systems in older individuals without dementia. Diabetes Care 2006;29(3):560-565.
  66. 66. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004;490(1-3):169-175.
  67. 67. Xu W, Caracciolo B, Wang HX, Winblad B, Backman L, Qiu C, et al. Accelerated Progression from Mild Cognitive Impairment to Dementia in People with Diabetes. Diabetes 2010;59(11):2928-35
  68. 68. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009;58(1):71-77.
  69. 69. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004;63(7):1181-1186.
  70. 70. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 2009;52(6):1031-1039.
  71. 71. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5(1):64-74.
  72. 72. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008;65(8):1066-1073.
  73. 73. Strachan MW, Price JF, Frier BM. Diabetes, cognitive impairment, and dementia. Bmj 2008;336(7634):6.
  74. 74. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007;56(1):211-216.
  75. 75. Gustafson D. Adiposity indices and dementia. Lancet Neurol 2006;5(8):713-720.
  76. 76. Whitmer RA. The epidemiology of adiposity and dementia. Curr Alzheimer Res 2007;4(2):117-122.
  77. 77. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005;62(10):1556-1560.
  78. 78. Xu W, Atti A, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Midlife overweight and obesity increase dementia risk in old age: a population-based twin study. Neurology 2011;76(18):1568-74.
  79. 79. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005;65(6):892-897.
  80. 80. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol 2006;63(9):1312-1317.
  81. 81. Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L. Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc 2008;56(1):111-116.
  82. 82. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol 2006;63(9):1312-1317.
  83. 83. Dahl AK, Lopponen M, Isoaho R, Berg S, Kivela SL. Overweight and obesity in old age are not associated with greater dementia risk. J Am Geriatr Soc 2008;56(12):2261-2266.
  84. 84. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64(10):1689-1695.
  85. 85. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2007;64(1):103-107.
  86. 86. Solomon A, Kareholt I, Ngandu T, Wolozin B, Macdonald SW, Winblad B, et al. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging 2007.
  87. 87. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292(18):2237-2242.
  88. 88. van den Berg E, Biessels GJ, de Craen AJ, Gussekloo J, Westendorp RG. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007;69(10):979-985.
  89. 89. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006;67(5):843-847.
  90. 90. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009;32(1):169-174.
  91. 91. Anttila T, Helkala EL, Viitanen M, Kareholt I, Fratiglioni L, Winblad B, et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ 2004;329(7465):539.
  92. 92. Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med 2005;352(3):245-253.
  93. 93. Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatry 2009;17(7):542-555.
  94. 94. Aggarwal NT, Bienias JL, Bennett DA, Wilson RS, Morris MC, Schneider JA, et al. The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiology 2006;26(3):140-146.
  95. 95. Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 2010;19(2):465-480.
  96. 96. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004;3(10):579-587.
  97. 97. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002;287(24):3230-3237.
  98. 98. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 2001;56(9):1188-1194.
  99. 99. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol1997;42(5):776-782.
  100. 100. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003;60(2):194-200.
  101. 101. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997;42(5):776-782.
  102. 102. Laitinen MH, Ngandu T, Rovio S, Helkala EL, Uusitalo U, Viitanen M, et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement Geriatr Cogn Disord 2006;22(1):99-107.
  103. 103. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B, et al. Apolipoprotein E epsilon4 Magnifies Lifestyle Risks for Dementia: A Population Based Study. J Cell Mol Med 2008.
  104. 104. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 2006;63(12):1709-1717.
  105. 105. Qiu C, Backman L, Winblad B, Aguero-Torres H, Fratiglioni L. The influence of education on clinically diagnosed dementia incidence and mortality data from the Kungsholmen Project. Arch Neurol 2001;58(12):2034-2039.
  106. 106. Evans DA, Hebert LE, Beckett LA, Scherr PA, Albert MS, Chown MJ, et al. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol 1997;54(11):1399-1405.
  107. 107. Borenstein AR, Wu Y, Mortimer JA, Schellenberg GD, McCormick WC, Bowen JD, et al. Developmental and vascular risk factors for Alzheimer's disease. Neurobiol Aging 2005;26(3):325-334.
  108. 108. Ngandu T, von Strauss E, Helkala EL, Winblad B, Nissinen A, Tuomilehto J, et al. Education and dementia: what lies behind the association? Neurology 2007;69(14):1442-1450.
  109. 109. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144(2):73-81.
  110. 110. Karp A, Paillard-Borg S, Wang HX, Silverstein M, Winblad B, Fratiglioni L. Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dement Geriatr Cogn Disord 2006;21(2):65-73.
  111. 111. Abbott RD, White LR, Ross GW, Masaki KH, Curb JD, Petrovitch H. Walking and dementia in physically capable elderly men. JAMA 2004;292(12):1447-1453.
  112. 112. Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 2005;4(11):705-711.
  113. 113. Crowe M, Andel R, Pedersen NL, Johansson B, Gatz M. Does participation in leisure activities lead to reduced risk of Alzheimer's disease? A prospective study of Swedish twins. J Gerontol B Psychol Sci Soc Sci 2003;58(5):P249-255.
  114. 114. Wilson RS, Bennett DA, Bienias JL, Mendes de Leon CF, Morris MC, Evans DA. Cognitive activity and cognitive decline in a biracial community population. Neurology 2003;61(6):812-816.
  115. 115. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002;287(6):742-748.
  116. 116. Andel R, Crowe M, Pedersen NL, Mortimer J, Crimmins E, Johansson B, et al. Complexity of work and risk of Alzheimer's disease: a population-based study of Swedish twins. J Gerontol B Psychol Sci Soc Sci 2005;60(5):P251-258.
  117. 117. Kroger E, Andel R, Lindsay J, Benounissa Z, Verreault R, Laurin D. Is complexity of work associated with risk of dementia? The Canadian Study of Health And Aging. American journal of epidemiology 2008;167(7):820-830.
  118. 118. Valenzuela MJ, Sachdev P, Wen W, Chen X, Brodaty H. Lifespan mental activity predicts diminished rate of hippocampal atrophy. PLoS One 2008;3(7):e2598.
  119. 119. Paillard-Borg S, Fratiglioni L, Xu W, Winblad B, Wang HX. An active lifestyle postpones dementia onset by more than one year in very old adults. J Alzheimers Dis Journal 2012;31(4):835-842.
  120. 120. Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet 2000;355(9212):1315-1319.
  121. 121. Wang HX, Karp A, Herlitz A, Crowe M, Kareholt I, Winblad B, et al. Personality and lifestyle in relation to dementia incidence. Neurology 2009;72(3):253-259.
  122. 122. Saczynski JS, Pfeifer LA, Masaki K, Korf ES, Laurin D, White L, et al. The effect of social engagement on incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 2006;163(5):433-440.
  123. 123. Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol 2006;5(5):406-412.
  124. 124. Wilson RS, Schneider JA, Bienias JL, Arnold SE, Evans DA, Bennett DA. Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology 2003;61(8):1102-1107.
  125. 125. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010;626(1):64-71.
  126. 126. Katon W, Lyles CR, Parker MM, Karter AJ, Huang ES, Whitmer RA. Association of depression with increased risk of dementia in patients with type 2 diabetes: the Diabetes and Aging Study. Arch Gen Psychiatry 2012;69(4):410-417.
  127. 127. DeLegge MH, Smoke A. Neurodegeneration and inflammation. Nutr Clin Pract 2008;23(1):35-41.
  128. 128. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Annal Neurology 2011;69(1):163-169.
  129. 129. Qiu C, Fratiglioni L, Karp A, Winblad B, Bellander T. Occupational exposure to electromagnetic fields and risk of Alzheimer's disease. Epidemiology 2004;15(6):687-694.
  130. 130. Qiu C, Karp A, von Strauss E, Winblad B, Fratiglioni L, Bellander T. Lifetime principal occupation and risk of Alzheimer's disease in the Kungsholmen project. Am J Ind Med 2003;43(2):204-211.
  131. 131. Feychting M, Jonsson F, Pedersen NL, Ahlbom A. Occupational magnetic field exposure and neurodegenerative disease. Epidemiology 2003;14(4):413-419; discussion 427-418.
  132. 132. Garcia AM, Sisternas A, Hoyos SP. Occupational exposure to extremely low frequency electric and magnetic fields and Alzheimer disease: a meta-analysis. Int J Epidemiol 2008;37(2):329-340.
  133. 133. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000;55(8):1158-1166.
  134. 134. Lye TC, Shores EA. Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol Rev 2000;10(2):115-129.
  135. 135. Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psychiatry 1990;53(5):373-378.
  136. 136. Guskiewicz KM, Marshall SW, Bailes J, McCrea M, Cantu RC, Randolph C, et al. Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery 2005;57(4):719-726; discussion 719-726.
  137. 137. Crawford FC, Vanderploeg RD, Freeman MJ, Singh S, Waisman M, Michaels L, et al. APOE genotype influences acquisition and recall following traumatic brain injury. Neurology 2002;58(7):1115-1118.
  138. 138. Groswasser Z, Reider G, II, Schwab K, Ommaya AK, Pridgen A, Brown HR, et al. Quantitative imaging in late TBI. Part II: cognition and work after closed and penetrating head injury: a report of the Vietnam head injury study. Brain Inj 2002;16(8):681-690.
  139. 139. Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. Psychol Med 2006;36(4):441-454.
  140. 140. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009;39(1):3-11.
  141. 141. Wang HX, Xu W, Pei JJ. Leisure activities, cognition and dementia. Biochimica et biophysica acta 2012;1822(3):482-491.
  142. 142. Lee Y, Back JH, Kim J, Kim SH, Na DL, Cheong HK, et al. Systematic review of health behavioral risks and cognitive health in older adults. Int Psychogeriatr 2010;22(2):174-187.
  143. 143. Laurin D, Masaki KH, Foley DJ, White LR, Launer LJ. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 2004;159(10):959-967.
  144. 144. Gray SL, Anderson ML, Crane PK, Breitner JC, McCormick W, Bowen JD, et al. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J Am Geriatr Soc 2008;56(2):291-295.
  145. 145. Savva GM, Stephan BC. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010;41(1):e41-46.
  146. 146. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 2009;4(1):e4144.
  147. 147. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008;16(5):343-354.
  148. 148. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence. Acta Neurol Scand Suppl 2006;185:50-57.
  149. 149. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011;12(5):e426-37.
  150. 150. Fratiglionia L, Qiu C. Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal. Lancet Neurol 2011;10(9): 819-828.

Written By

Weili Xu, Camilla Ferrari and Hui-Xin Wang

Submitted: April 24th, 2012 Published: February 27th, 2013